Top Section/Ad
Top Section/Ad
Most recent
Calendar quirk could keep issuance going in December
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
More articles/Ad
More articles/Ad
More articles
-
German pharmaceuticals platform breaks the ice for large cap listings in Europe this year
-
It could take years to develop a gene therapy to slow aging, but much less for big pharma to scoop up Genflow Biosciences
-
PRA to return to risk-weighted asset-based calculation for Pillar 2A
-
The pandemic has helped the Swiss online pharmacy to boost its business
-
Emerging markets reliant upon tourism find relief
-
German medical company is working towards reinclusion in the SDax